September 12, 2011
Kissei Pharmaceutical announced on September 1 a license agreement with SpePharm Holding B.V. of the Netherlands that grants Kissei the rights to develop and market dexrazoxane for the treatment of anthracycline-induced extravasation in Japan. Kissei will obtain license to a...read more